August 2004

Jane S. Ricciuti, RPh, MS

August 18, 2004

Introduction

The US Food and Drug Administration (FDA) approved Campral (acamprosate) for the maintenance of abstinence in alcohol-dependent patients by altering the normal balance between neuronal excitation and inhibition.

Botox Cosmetic (botulinum toxin type A) received a supplemental approval for the treatment of primary axillary hyperhidrosis. Botulinum toxin is thought to stop release of acetylcholine, temporarily blocking the nerves in the underarm that stimulate sweating.

This month's column reviews FDA new product approvals and labeling changes for:

Anti-infective Agents

Alinia (nitazoxanide) Oral Suspension and Tablets

Dermatologic Agents

Botox Cosmetic (Botulinum Toxin Type A)

Nonsteroidal Anti-inflammatory Agents

Mobic (meloxicam) Tablets

Oncologic Agents

Aldara (imiquimod) Topical Cream

Psychopharmacologic Agents

Campral (acamprosate) Tablets

1 2 3 4 5 6

Next Section

Cite this: August 2004 - Medscape - Aug 18, 2004.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

August 2004

Introduction

Tables

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback